A kinase inhibitor targeting PDGFRA and/or FGFR or other frequently activated tyrosine kinases that can reach effective intra-tumor concentrations before dose limiting toxicity is a likely candidate for a combination with an EGFR inhibitor for a potentially more effective therapy. Here, EGFR is linked to neoplasm.